english

研究業績

2024

  • Efthymiou S, Han W, Ilyas M, Li J, Yu Y, Scala M, Malintan N T, Ilyas M, Vavouraki N, Mankad K, Maroofian R, Rocca C, Salpietro V, Lakhani S, Mallack E J, Palculict T B, Li H, Zhang G, Zafar F, Rana N, Takashima N, Matsunaga H, Manzoni C, Striano P, Lythgoe M F, Aruga J, Lu W, and Houlden H. Human mutations in SLITRK3 implicated in GABAergic synapse development in mice. Front Mol Neurosci 2024; 17. 1222935. (doi: 10.3389/fnmol.2024.1222935)

2022

  • Hatayama M, Aruga J: SLITRK1-mediated noradrenergic projection suppression in the neonatal prefrontal cortex. Front Mol Neurosci 2022; 15:1080739. (doi: 10.3389/fnmol.2022.1080739)
  • Fujita W, Uchida H, Kawanishi M, Kuroiwa Y, Abe M, Sakimura K.: Receptor Transporter Protein 4 (RTP4) in the Hypothalamus Is Involved in the Development of Antinociceptive Tolerance to Morphine. Biomolecules. 2022; 12:1471. (doi: 10.3390/biom12101471)
  • Hatayama M, Katayama KI, Kawahara Y, Matsunaga H, Takashima N, Iwayama Y, Matsumoto Y, Nishi A, Yoshikawa T, Aruga J: SLITRK1-mediated noradrenergic projection suppression in the neonatal prefrontal cortex. Commun Biol 2022; 5:935. (doi: 10.1038/s42003-022-03891-y)
  • Katayama K, Morimura N, Kobayashi K, Corbett D, Okamoto T, Ornthanalai VG, Matsunaga H, Fujita W, Matsumoto Y, Akagi T, Hashikawa T, Yamada K, Murphy NP, Nagao S, Aruga J: Slitrk2 deficiency causes hyperactivity with altered vestibular function and serotonergic dysregulation. iScience 2022; 25:104604. (doi: 10.1016/j.isci.2022.104604)
  • Ichise M, Sakoori K, Katayama KI, Morimura N, Yamada K, Ozawa H, Matsunaga H, Hatayama M, Aruga J: Leucine-Rich Repeats and Transmembrane Domain 2 controls protein sorting in the striatal projection system and its deficiency causes disturbances in motor responses and monoamine dynamics. Front Mol Neurosci 2022;15:856315. (doi: 10.3389/fnmol.2022.856315)

2021

  • Matsunaga H, Aruga J: Trans-synaptic regulation of metabotropic glutamate receptors by Elfn proteins in health and disease. Front Neural Circuits. 2021;15:634875. (doi: 10.3389/fncir.2021.634875)
  • Maekawa R, Muto H, Hatayama M, Aruga J: Dysregulation of erythropoiesis and altered erythroblastic NMDA receptor-mediated calcium influx in Lrfn2-deficient mice. PLoS One. 2021;16:e0245624. (doi: 10.1371/journal.pone.0245624)
  • Watanabe D, Nakagawa S, Morofuji Y, Tóth AE, Vastag M, Aruga J, Niwa M, Deli MA: Characterization of a primate Blood-Brain Barrier co-Culture model prepared from primary brain endothelial cells, pericytes and astrocytes. Pharmaceutics 2021;13:1484. (doi: 10.3390/pharmaceutics13091484)

2020

  • Fujita W, The possible role of MOPr-DOPr heteromers and its regulatory protein RTP4 at sensory neurons in relation to pain perception. Front Cell Neurosci. 2020; 14:609362. (doi: 10.3389/fncel.2020.609362)
  • Fujita W. Aiming at ideal therapeutics-MOPr/DOPr or MOPr-DOPr heteromertargeting ligand. Curr Top Med Chem. 2020; 20:2843-2851. (doi: 10.2174/1568026620666200423095231)

2019

  • Nakagawa S, Aruga J: Sphingosine 1-phosphate signaling is involved in impaired blood-brain barrier function in ischemia-reperfusion injury. Mol Neurobiol. 2019; PMID: 31802363 (doi: 10.1007/s12035-019-01844-x)

2018

  • Odaka YS, Tohmonda T, Toyoda A, Aruga J: An evolutionarily conserved mesodermal enhancer in vertebrate Zic3. Sci Rep. 2018;8:14954.
  • Tohmonda T, Kamiya A, Ishiguro A,Iwaki T, Fujimi TJ, Hatayama M, Aruga J: Identification and characterization of novel conserved domains in metazoan Zic proteins. Mol Biol Evol. 2018 PMID: 29905849 (doi: 10.1093/molbev/msy122)
  • Ishiguro A, Hatayama M, Otsuka MI, Aruga J: Link between the causative genes of holoprosencephaly: Zic2 directly regulates Tgif1 expression. Sci Rep. 2018;8(1):2140. (doi: 10.1038/s41598-018-20242-2)
  • Aruga J, Hatayama M: Comparative Genomics of the Zic Family Genes. Adv Exp Med Biol. 2018;1046:3-26. (doi: 10.1007/978-981-10-7311-3_1)
  • Aruga J: Lophotrochozoan Zic Genes. Adv Exp Med Biol. 2018;1046:69-86. (doi: 10.1007/978-981-10-7311-3_5)
  • Aruga J: Zic Family Proteins in Emerging Biomedical Studies. Adv Exp Med Biol. 2018;1046:233-248. (doi: 10.1007/978-981-10-7311-3_12)
  • Aruga J, Millen KJ: ZIC1 Function in Normal Cerebellar Development and Human Developmental Pathology. Adv Exp Med Biol. 2018;1046:249-268. (doi: 10.1007/978-981-10-7311-3_13)
  • Hatayama M, Aruga J: Role of Zic Family Proteins in Transcriptional Regulation and Chromatin Remodeling. Adv Exp Med Biol. 2018;1046:353-380. (doi: 10.1007/978-981-10-7311-3_18)
  • Masago K, Kihara Y, Yanagida K, Hamano F, Nakagawa S, Niwa M, Shimizu T: Lysophosphatidic acid receptor, LPA6, regulates endothelial blood-brain barrier function: Implication for hepatic encephalopathy. Biochem Biophys Res Commun. 2018; 501(4):1048-1054. (doi: 10.1016/j.bbrc.2018.05.106)
  • Ueda H, Matsunaga H, Matsushita Y, Maeda S, Iwamoto R, Yokoyama S, Shirouzu M: Ecto-F0/F1 ATPase as a novel candidate of prothymosin α receptor. Expert Opin Biol Ther. in press.
  • 有賀 純: LRRシナプスオーガナイザーと神経発達障害. BIO INDUSTRY, 35(2):24–33. 2018
  • Jun Aruga (Ed):Zic family - Evolution, Development and Disease. Springer. eBook ISBN: 978-981-10-7311-3; DOI: 10.1007/978-981-10-7311-3; Hardcover ISBN: 978-981-10-7310-6. 2018

2017

  • Morimura N, Yasuda H, Yamaguchi K, Katayama KI, Hatayama M, Tomioka NH, Odagawa M, Kamiya A, Iwayama Y, Maekawa M, Nakamura K, Matsuzaki H, Tsujii M, Yamada K, Yoshikawa T, Aruga J: Autism-like behaviours and enhanced memory formation and synaptic plasticity in Lrfn2/SALM1-deficient mice. Nat Commun. 2017;8:15800. (doi: 10.1038/ncomms15800)

2016

  • Fukuda S, Nakagawa S, Tatsumi R, Morofuji Y, Takeshita T, Hayashi K, Tanaka K, Matsuo T, Niwa M: Glucagon-Like Peptide-1 Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells Under Basal and Hyperglycemia Conditions. J Mol Neurosci, 59(2):211-219, 2016 (doi: 10.1007/s12031-015-0696-1)

2015

  • So G, Nakagawa S, Morofuji Y, Hiu T, Hayashi K, Tanaka K, Suyama K, Deli MA, Nagata I, Matsuo T, Niwa M: Candesartan Improves Ischemia-Induced Impairment of the Blood-Brain Barrier In Vitro. Cell Mol Neurobiol. 2015;35(4):563-572. (doi: 10.1007/s10571-014-0152-8)
  • 有賀純:Dandy-Walker症候群. Clinical Neuroscience¸33(4):397-401. 2015

2014

  • Tomioka NH, Yasuda H, Miyamoto H, Hatayama M, Morimura N, Matsumoto Y, Suzuki T, Odagawa M, Odaka YS, Iwayama Y, Um JW, Ko J, Inoue Y, Kaneko S, Hirose S, Yamada K, Yoshikawa T, Yamakawa K, Aruga J: Elfn1 recruits presynaptic mGluR7 in trans and its loss results in seizures. Nature Communications 5:4501, 2014 (doi: 10.1038/ncomms5501)
  • Yamada N, Nakagawa S, Horai S, Tanaka K, Deli MA, Yatsuhashi H, Niwa M: Hepatocyte growth factor enhances the barrier function in primary cultures of rat brain microvascular endothelial cells. Microvascular Research 92:41-49, 2014 (doi: 10.1016/j.mvr.2013.12.004.)
  • Takeshita T, Nakagawa S, Tatsumi R, So G, Hayashi K, Tanaka K, Deli MA, Nagata I, Niwa M: Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling. Molecular and Cellular Neuroscience 60:1-9, 2014( doi: 10.1016/j.mcn.2014.01.006.)
  • 中川慎介、丹羽正美: 血液脳関門(BBB)構成細胞の単離と in vitro BBBモデルの再構築. 日本薬理学雑誌 143: 137-143, 2014

2013

  • Shoji Horai, Shinsuke Nakagawa, Kunihiko Tanaka, Yoichi Morofuji, Pierre-Olivier Couraud, Maria A. Deli, Hiroki Ozawa, Masami Niwa: Cilostazol strengthens barrier integrity in brain endothelial cells. Cell Mol Neurobiol 33: 291-307, 2013 (doi: 10.1007/s10571-012-9896-1)
  • Toyoda K, Tanaka K, Nakagawa S, Thuy DHD, Ujifuku K, Kamada K, Hayashi K, Matsuo T, Nagata I, Niwa M: Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: A new in vitro blood-brain barrier model. Cell Mol Neurobiol 33: 489-501, 2013 (doi: 10.1007/s10571-013-9913-z)

理研旧行動発達障害研究チームの研究業績

トップへ戻るボタン